The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance.

摘要: When P-glycoprotein (PGP) was first identified as a direct mediator of multidrug resistance (MDR) great deal excitement generated scientists and clinicians anticipated the ability to successfully treat previously refractory cancers by blocking this drug efflux pump. More than twenty years later there is still minimal evidence that inhibiting PGP will have widespread impact on chemosensitivity human tumors. Yet, we know over-expressed in many cancers, associated with poor prognosis certain tumor types and, if functional, certainly reduce accumulation common anticancer drugs inside cells exhibiting elevated levels. Similar situations arisen more recently for other potential mediators such apoptosis antagonist protein Bcl-2. Bcl-2 has been linked patient numerous studies. There interest expression or function increase susceptibility apoptotic stimuli chemotherapy. However, preclinical clinical supporting approach unilateral means significantly enhancing response tumors chemotherapy limited. In view these examples, it would appear likely similar caveats be experienced future new molecular targets are MDR reversal. Given ever increasing genetic diversity cancer development progression, should not surprising also complex heterogeneous. Consequently, solutions problem unlikely arise from interventions aimed at any single mechanism. These concepts suggest approaches addressing various pharmacological features necessary order make significant in-roads into improving activity current agents. This review summarizes directions being taken overcome how liposomal delivery systems may play an important role achieving aim.